Dass joins Masood Khan, senior director of immunoanalytical science and technology at the Shawnee, Kansas-based firm. He will assist with the development of GLP-compliant and non-GLP assays for the conduct of large molecule bioanalytical studies, including PK/TK analysis, immunogenicity evaluation and biomarker quantification.
KCAS uses state-of-the-art immunoanalytical technologies to support large molecule bioanalysis for preclinical and clinical studies (Phase I - IV), as well as rapid bioanalysis for biomarker screening pilot projects.
‘We are very fortunate to have both Dr Khan and Dr Dass at KCAS,’ said president and scientific director Dari Dadgar.
‘Their combined knowledge and skill in working with large molecules, specifically LBA services, has positively impacted our capabilities and we look forward to propelled growth and expansion in the future.’
KCAS has recently purchased Meso Scale Discovery’s Sector Imager 6000, an electrochemiluminescence (ECL) detection technology, which will enable the company to offer immunogenicity assays with better drug tolerance and multi-plex panels for biomarker assays.
KCAS expands ligand binding assay team
Proveen Dass joins the company as associate director
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
The path to commercial allogeneic iPSC therapies
The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Manufacturing
Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference
By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development
Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies
Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Manufacturing
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration
CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanised monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months